Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

Battenin

From Wikipedia, the free encyclopedia
(Redirected from CLN3)
CLN3
Identifiers
AliasesCLN3, BTS, JNCL, ceroid-lipofuscinosis, neuronal 3, battenin, BTN1, CLN3 lysosomal/endosomal transmembrane protein, battenin
External IDsOMIM: 607042; MGI: 107537; HomoloGene: 37259; GeneCards: CLN3; OMA:CLN3 - orthologs
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001146311
NM_009907
NM_001329789

RefSeq (protein)
Location (UCSC)Chr 16: 28.47 – 28.5 MbChr 7: 126.57 – 126.59 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Battenin is a protein that in humans is encoded by the CLN3 gene located on chromosome 16.[5][6] Battenin is not clustered into any Pfam clan, but it is included in the TCDB suggesting that it is a transporter.[7] In humans, it belongs to the atypical SLCs[7][8] due to its structural and phylogenetic similarity to other SLC transporters.

Function

[edit]

Battenin is involved in lysosomal function. Many alternatively spliced transcript variants have been found for this gene.[6]

Battenin is a transmembrane protein predicted to be composed of 11 transmembrane helices,[8] yet no crystal structure is available.

Clinical significance

[edit]

Mutations in this gene, as well as other neuronal ceroid-lipofuscinosis (CLN) genes, cause neurodegenerative diseases commonly known as Batten disease, also known as Juvenile Neuronal Ceroid Lipofuscinosis (JNCL) or Juvenile Batten disease.

References

[edit]
  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000188603 Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000030720 Ensembl, May 2017
  3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. Rusyn E, Mousallem T, Persaud-Sawin DA, Miller S, Boustany RM (June 2008). "CLN3p impacts galactosylceramide transport, raft morphology, and lipid content". Pediatric Research. 63 (6): 625–31. doi:10.1203/PDR.0b013e31816fdc17. PMID 18317235.
  6. 1 2 "Entrez Gene: CLN3 ceroid-lipofuscinosis, neuronal 3, juvenile (Batten, Spielmeyer-Vogt disease)".
  7. 1 2 Perland E, Fredriksson R (March 2017). "Classification Systems of Secondary Active Transporters". Trends in Pharmacological Sciences. 38 (3): 305–315. doi:10.1016/j.tips.2016.11.008. PMID 27939446.
  8. 1 2 Perland E, Bagchi S, Klaesson A, Fredriksson R (September 2017). "Characteristics of 29 novel atypical solute carriers of major facilitator superfamily type: evolutionary conservation, predicted structure and neuronal co-expression". Open Biology. 7 (9) 170142. doi:10.1098/rsob.170142. PMC 5627054. PMID 28878041.

Further reading

[edit]
[edit]